BELITE BIO, INC cotiza a 151.87 USD y tiene una capitalización bursátil de $6.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervent…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.68 | $-0.70 |
| Estimado | $-0.77 | $-0.78 | $-0.64 | $-0.54 |
| Sorpresa | — | — | -6.3% | -29.6% |
| Métrica | BLTE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -10.1% | -40.4% | +30.3% |
| ROA | -9.9% | -32.0% | +22.1% |
| Current Ratio | 50.02 | 2.84 | +47.18 |
| Debt / Equity | — | 0.28 | — |